To address these limitations, peptide-based tumour-activated inhibitors like CLP002 (TR3-M-NP) have been developed—a 9-amino-acid anti-PD-L1 peptide conjugated to a PEG chain that forms protective nanoparticles in circulation (Figure 19) [46,142]. The gene discussed is CD274; the disease is neoplasm.